Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo

The antitumor activity of vandetanib [a multiple signal transduction inhibitor including the RET tyrosine kinase, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) receptor (VEGFR), ERK and with antiangiogenic activity], in primary anaplastic thyroid cancer (ATC) cel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology reports 2018-05, Vol.39 (5), p.2306-2314
Hauptverfasser: Ferrari, Silvia Martina, Bocci, Guido, Di Desidero, Teresa, Ruffilli, Ilaria, Elia, Giusy, Ragusa, Francesca, Fioravanti, Anna, Orlandi, Paola, Paparo, Sabrina Rosaria, Patrizio, Armando, Piaggi, Simona, La Motta, Concettina, Ulisse, Salvatore, Baldini, Enke, Materazzi, Gabriele, Miccoli, Paolo, Antonelli, Alessandro, Fallahi, Poupak
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The antitumor activity of vandetanib [a multiple signal transduction inhibitor including the RET tyrosine kinase, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) receptor (VEGFR), ERK and with antiangiogenic activity], in primary anaplastic thyroid cancer (ATC) cells, in the human cell line 8305C [undifferentiated thyroid cancer (TC)] and in an ATC‑cell line (AF), was investigated in the present study. Vandetanib (1 and 100 nM; 1, 10, 25 and 50 µM) was tested by WST‑1, apoptosis, migration and invasion assays: in primary ATC cells, in the 8305C continuous cell line, and in AF cells; and in 8305C cells in CD nu/nu mice. Vandetanib significantly reduced ATC cell proliferation (P
ISSN:1021-335X
1791-2431
DOI:10.3892/or.2018.6305